ENTRY D10316 Drug NAME Nivolumab (USAN/INN); Nivolumab (genetical recombination) (JAN); Opdivo (TN) PRODUCT OPDIVO (E.R. Squibb & Sons) OPDIVO QVANTIG (E.R. Squibb & Sons) FORMULA C6362H9862N1712O1995S42 EXACT_MASS 143509.1148 MOL_WEIGHT 143597.46 SEQUENCE (Heavy chain) QVQLVESGGG VVQPGRSLRL DCKASGITFS NSGMHWVRQA PGKGLEWVAV IWYDGSKRYY ADSVKGRFTI SRDNSKNTLF LQMNSLRAED TAVYYCATND DYWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSLGK (Light chain) EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ SSNWPRTFGQ GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC (Disulfide bridge: H22-H96, H127-L214, H140-H196, H219-H'219, H222-H'222, H254-H314, H360-H418, H'22-H'96, H'127-L'214, H'140-H'196, H'254-H'314, H'360-H'418, L-23-L88, L134-L194, L'23-L'88, L'134-L'194) TYPE Peptide CLASS Antineoplastic DG02938 Immune checkpoint inhibitor REMARK Therapeutic category: 4291 ATC code: L01FF01 Product: D10316 Product (mixture): D12334 EFFICACY Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody DISEASE Melanoma [DS:H00038] Non-small cell lung cancer [DS:H00014] Small cell lung cancer [DS:H00013] Malignant pleural mesothelioma [DS:H00015] Renal cell carcinoma [DS:H00021] Hodgkin lymphoma [DS:H00007] Squamous cell carcinoma of the head and neck [DS:H02420] Urothelial carcinoma [DS:H00022] Colorectal cancer (MSI-H or dMMR) [DS:H00020] Hepatocellular carcinoma [DS:H00048] Esophageal squamous cell carcinoma [DS:H00017] Gastric cancer [DS:H00018] Esophageal adenocarcinoma [DS:H00017] TYPE Monoclonal antibody TARGET PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744] PATHWAY hsa04514(5133) Cell adhesion molecules hsa04660(5133) T cell receptor signaling pathway hsa05235(5133) PD-L1 expression and PD-1 checkpoint pathway in cancer INTERACTION BRITE Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES L01FF PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors L01FF01 Nivolumab D10316 Nivolumab (USAN/INN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Monoclonal Antibody/Antibody-Drug Conjugate Anti-PD1 Antibodies Nivolumab D10316 Nivolumab (USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D10316 Nivolumab (USAN/INN); Nivolumab (genetical recombination) (JAN) Drug groups [BR:br08330] Antineoplastic DG02938 Immune checkpoint inhibitor D10316 Nivolumab Drug classes [BR:br08332] Antineoplastic DG02938 Immune checkpoint inhibitor D10316 Nivolumab Target-based classification of drugs [BR:br08310] Cell surface molecules and ligands Other cell surface molecules Immune checkpoints PDCD1 (PD1, CD279) D10316 Nivolumab (USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10316 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10316 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10316 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10316 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D10316 DBLINKS CAS: 946414-94-4 PubChem: 163312346 ///